Enterprise Value to EBITDA Ratio: Salarius Pharmaceuticals (SLRX)
Salarius Pharmaceuticals (SLRX) operates as a biotech startup that has fully outsourced substance synthesis and testing to external contractors. The firm's success relies on the efficacy of its rare tumor therapies and the acquisition of specific regulatory statuses. This daily price chart, featuring an EV/EBITDA metric of 0.00, highlights the risks of a single-product approach, where the business's fate depends directly on the outcome of a narrow set of clinical trials.
Analytical breakdowns for Salarius Pharmaceuticals
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Salarius Pharmaceuticals|SLRX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Salarius Pharmaceuticals, Inc.|SLRX - Company Aggregate Debts|Debt to Book Capitalization Ratio Salarius Pharma|SLRX - Company Long-Term Debt|Company Short-Term Debts Salarius Pharmaceuticals|Quick Liquidity salariuspharma.com
- business earnings and investment ratios data:
SLRX - Final Profit|Projected Future Earnings Salarius Pharmaceuticals|SLRX - Business Payback Period|Projected Price to Earnings Salarius Pharmaceuticals|SLRX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Salarius Pharma|SLRX - Operating income before deduction of amortization|Net earnings per share for the last 12 months Salarius Pharmaceuticals|SLRX - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months salariuspharma.com|SLRX - Earnings per share trend in current year|Earnings growth forecast for next year Salarius Pharmaceuticals
- company sales and revenue statistics:
Fundamental company analysis:SLRX (Salarius)
By outsourcing production and testing, Salarius Pharmaceuticals (SLRX) minimizes capital expenditures, making a business valuation analysis via EV/EBITDA particularly revealing. This multiple compares the company's total enterprise value with its operating profit before interest and taxes, uncovering the real efficiency of its assets. It is critical for investors to correlate this calculation with the company's EV/EBITDA chart trend to distinguish fundamental undervaluation from stagnation risks.
Who Salarius Pharmaceuticals competes with
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|Total Company Value to Operating Income Before Depreciation Ratio delcath.com|EV/EBITDA Multiple YMAB (Y-mAbs Therapeutics, Inc.)|EV/EBITDA Multiple Aura Biosciences Inc AURA|CADL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ARAY: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SLS: EV/EBITDA Multiple|actuatetherapeutics.com (ACTU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|Total Company Value to Operating Income Before Depreciation Ratio Fate Pharma|Aadi Bioscience - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple TScan Therapeutics Inc TCRX|CSBR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio XBiotech Inc. XBIT|CVM (cel-sci.com) - Enterprise Value to EBITDA Ratio|OS Therapies, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Radiopharm Theranostics|Artiva - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ANL|VERU (Veru Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TPST (Tempest Tx)|EV/EBITDA Multiple Xilio Therapeutics Inc XLO|RENB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation MURA (Mural Oncology plc)|kairospharma.com (KAPA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio OnKure Therapeutics|GDTC (CytoMed Therapeutics Ltd) - EV/EBITDA Multiple|EV/EBITDA Multiple Curis Corp|EV/EBITDA Multiple APLM|Enterprise Value to EBITDA Ratio tharimmune.com THAR|EV/EBITDA Multiple ADVB (Advanced Biomed)|Genprex Inc. (GNPX) - Company Value to EBITDA|CLDI: Enterprise Value to EBITDA Ratio|SBFM - EV/EBITDA Multiple|XBIO (xeneticbio.com) - Enterprise Value to EBITDA Ratio|PPBT: Enterprise Value to Operating Income Before Depreciation Ratio|AONC (American Oncology Network Inc) - EV/EBITDA Multiple|BeiGene Ltd. (BGNE) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CKPT|Enterprise Value to EBITDA Ratio Elevation Oncology Inc. ELEV|EV/EBITDA Multiple ICAD (iCAD)|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VIRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MorphoSys Corp (MOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NAYA - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group
